Concurrent OPA1 mutation and chromosome 3q deletion leading to Behr syndrome: a case report

Ting Zeng¹,², Linyan Liao¹, Yi Guo¹, Xuxu Liu¹, Xiaobo Xiong¹, Yu Zhang¹,², Shi Cen¹,², Honghui Li¹,² and Shuzhang Wei¹,²*

Abstract

Background: Optic atrophy 1 (OPA1) gene mutations are associated with dominantly inherited optic neuropathy resulting in a progressive loss of visual acuity. Compound heterozygous or homozygous variants that lead to severe phenotypes, including Behr syndrome, have been reported rarely.

Case presentation: Here, we present a 14-month-old boy with early onset optic atrophy, congenital cataracts, neuromuscular disorders, mental retardation, and developmental delay. Combined genetic testing, including whole exome sequencing (WES) and chromosomal microarray analysis, revealed a concurrent OPA1 variant (c.2189 T > C p.Leu730Ser) and de novo chromosome 3q deletion as pathogenic variants leading to the severe phenotype.

Conclusions: Our case is the first reporting a novel missense OPA1 variant co-occurring with a chromosomal microdeletion leading to a severe phenotype reminiscent of Behr syndrome. This expands the mutation spectrum of OPA1 and inheritance patterns of this disease.

Keywords: OPA1, Optic atrophy, Behr syndrome, Microdeletion, Case report

Background

The optic atrophy 1 (OPA1) gene encodes a dynamin-related protein located within the mitochondrial inner membrane, and is involved in multiple critical cellular and mitochondrial functions [1]. Variants in the OPA1 gene are mostly related with autosomal dominant optic atrophy (DOA) (OMIM#165500) [2-5]. This disorder is characterized by an insidious onset of visual impairment in early childhood with moderate to severe loss of visual acuity, temporal optic disc pallor, color vision deficits, and centrocecal scotoma of variable density. Dominant optic atrophy plus (DOA+) syndrome is observed in 20% of patients with pathogenic OPA1 variants [4-6], manifesting extra-neuromuscular features like ataxia, myopathy, peripheral neuropathy, sensorineural deafness, and chronic progressive external ophthalmoplegia.

To date, over 500 pathogenic variants have been documented in OPA1 genes that are inherited in a dominant manner, with an estimated prevalence at 1/50,000 [7]. OPA1 variants with a recessive inheritance mode that cause the Behr syndrome have been recently revealed in a few cases with early-onset optic atrophy [8, 9], spino-cerebellar degeneration, mental retardation, and developmental delay [10]. Clinical heterogeneity has been observed in patients with compound heterozygous or homozygous variants of the OPA1 gene [11]. Here, we report a boy with a hemizygous OPA1 variant unmasked by concurrent chromosome 3q deletion. The patient showed early onset and progressive optic atrophy, peripheral neuropathy, and developmental delay resembling...
Behr syndrome. This case could help extend the phenotypic and genotypic spectrum of the disorder.

Case presentation
Clinical data
A 14-month-old boy was referred to the department of Developmental Behavior Pediatrics at Liuzhou Maternity and Child Healthcare Hospital, Guangxi province, for developmental delay, Achilles tendon contracture, hypertonia, nystagmus, and vision defects. The boy was born at full term following an uneventful pregnancy to non-consanguineous parents of Chinese descent. Neither of the parents nor their related family members had any related symptoms.

The boy had normal birth length and weight (52 cm and 3.3 kg) and is now 80 cm and 10.8 kg (update to 17/4/2019). The parents described the boy failing to track light or objects, and nystagmus was noticed since birth. Ophthalmological examination revealed no eye tracking, horizontal tremor of both eyes, exotropia, and corneal transparency. Congenital cataracts were found in the patient. No abnormalities were found in the ophthalmological evaluations for the father of the proband.

Developmental milestones were obviously delayed. He could not roll over until 12 months, or get to a sitting position without assistance until 18 months. The boy has had hypertonia and Achilles tendon contracture since birth. The Gesell developmental test was performed and the boy was evaluated a shaving severe developmental delay of adaptability and fine motor skills, moderate developmental delay of large motor skills, and mild developmental delay of language development and personal-social interactions. Magnetic resonance imaging revealed delayed myelination of the brain and formation of the fifth ventricle (Fig. 1). Karyotyping showed normal 46, XY. Tandem mass spectrometry was applied to detect possible inherited metabolic diseases for the proband but with negative results. Genetic testing and data analysis.

Genomic DNA was extracted from peripheral blood samples of the patient and his parents using the GentraPuregene Blood Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Proband-only targeted next-generation sequencing using an inherited disease panel (including 2742 disease-causing genes, cat No. 5190–7519, Agilent Technologies, Santa Clara, CA, USA) was performed as described previously [12]. Original sequencing data were assessed using Fast QC (version 0.11.2) for quality control. The Burrows-Wheeler Alignment tool (version 0.2.10) was employed for aligning sequencing data to the Human Reference Genome (NCBI build 37, hg 19). Single nucleotide variants and small indels were identified by the Genome Analysis Toolkit. All variants were saved in Variant Call Format and uploaded to the Ingenuity Variant Analysis (Ingenuity Systems, Redwood City, CA, USA) and TGex (Translational Genomics Expert) platforms for biological analysis and interpretation. Variants detected by next-generation sequencing were confirmed by Sanger sequencing in the patient and his parents.

Copy number variants (CNVs) were identified using CNVkit open source software, a tool kit to infer and visualize copy numbers from targeted DNA sequencing data. Aligned data after the Burrows-Wheeler Alignment process were used as input. Normal reference data used for CNV identification were constructed using sequencing data from 10 normal males and 10 normal females that were previously validated without pathogenic CNVs by a chromosomal microarray platform. Default CNVkit settings were used for CNV identification. CNVs detected through bioinformatics analysis are further validated by chromosomal array analysis using CytoScan 750 k Suite (Thermo Scientific, Waltham, MA, USA).

A homozygous variant in OPA1 (NM_015560: c.2189 T > C p.Leu730Ser) was identified in the patient. The variant is absent from all currently available databases including the Genome Aggregation Database. Multiple lines of computational evidence suggest a deleterious effect of this mutation (Table 1). Sanger sequencing was applied to validate the variant in the pedigree and revealed that the patient’s father carried the same heterozygous variant and his mother was wild-type (Fig. 2a). CNV analysis, based on read-depth information of the proband, indicated a heterozygous deletion on the short arm of chromosome 3 (Fig. 2b). Chromosomal microarray analysis confirmed this deletion as arr[GRCh37] 3q28q29(191921285_195896838)x1(Fig. 2c). Thus, the proband inherited a heterozygous variant in OPA1 gene from his father and developed a de novo 3975 kb microdeletion on chromosome 3 that unmasked the heterozygous variant into a hemizygous form.

Fig. 1 Brain magnetic resonance images at 14 months of age. The images show delayed myelination for this age
reported that defined and identified in hundreds of patients. Ban et al. under a dominant inheritance pattern, has been well-chondrial inner membrane leading to optic atrophy codes a multifunctional protein located within the mito-

fibers induced by $\text{OPA1}$ single-fiber level, and greater mitochondrial DNA prolif-

increase in the mitochondrial DNA copy number at the phenotype, presenting extra-ocular manifestations. Yu-

$\text{OPA1}$ with only one membrae tabulation. Twenty percent of those patients excluding cardiolipin association, GTP hydrolysis, and DOA displayed selective defects in several activities, in-

ruates and identified biallelic $\text{OPA1}$ mutations in these cases with biallelic $\text{OPA1}$ variants. Alessia et al. [15] reviewed reported mutations and a possible dosage effect of the phenotypes. This indicated clinical heterogeneity of one of the mutations and also manifested mild related individuals [14]. Each parent was heterozygous for opt atrophy with a severe neuromuscular phenotype and a reces-

ment. Thus, the severe neuromuscular and develop-

mental phenotypes in our patient further supported this unique case also emphasized the importance of consistent with OPA without any neurologic involve-

In conclusion, we report a unique case of optic atrophy, congenital cataracts, neuromus-

cular disorders, mental retardation, and developmental delay reminiscent of Behr syndrome, expanding the mutation spectrum of $\text{OPA1}$. The genetic findings in this unique case also emphasized the importance of CNVs analysis in diagnosis protocol of Behr syndrome.

In conclusion, we report a unique case of optic atrophy with a severe neuromuscular phenotype and a recessive inheritance mode. The missense variant, $c.2189\ T \rightarrow C$ encoded by the $\text{OPA1}$ gene, thought to contribute consistently to modulating the phenotype in $\text{OPA1}$ compound heterozygous subjects, suggestive of either recessive or semi-dominant patterns of inheritance in those DOA+ patients with biallelic $\text{OPA1}$ variants.

The Behr syndrome is characterized by early-onset optic atrophy, ataxia, pyramidal signs, peripheral neuropathy, mental retardation, and developmental delay [8, 16]. Bonneau et al. [8] reported four unrelated children with a phenotype consistent with Behr syndrome. Three of the four patients carried a truncating mutation on one allele and the same missense mutation (Ile382Met) on the other allele. Co-

 occurrence of a truncating $\text{OPA1}$ mutation with another missense mutation may result in a dominant-

negative effect and a more severe phenotype, particu-

larly if the missense mutation occurs in the GTPase domain of the protein. Only two patients with homo-

zygous missense mutations in $\text{OPA1}$ have been reported to date [17, 18]. The missense mutation identified in our patient was first recognized as homozygous, but later proved to be hemizygous by further definition of the concurrent chromosomal microdeletion. This is thought to be extremely rare compared with reported dominant or recessive inheritance modes, thus rapid molecular analysis revealing underlying pathogenic variants is of great importance in those confusing clinical case.

Genomic rearrangements, including larger deletions or duplications, are frequent in patients with optic atrophy [19]. This indicates that the hypothesis that haploinsufficiency could be a major pathologic mechan-

ism in $\text{OPA1}$ mutations associated with autosomal DOA [20]. Although the 3975 kb deletion also covered disease-related genes $\text{FGF12}$ and $\text{TFRC}$, none of them was an established haploinsufficiency gene or with reported pathogenic deletions in patients. To our knowledge, all patients with exonic or chromosomal deletions encompassing $\text{OPA1}$ exhibited symptoms consistent with OPA without any neurologic involve-

ment. Thus, the severe neuromuscular and develop-

mental phenotypes in our patient further supported the recessive pathogenic mode in our proband. Optic atrophy was evident in all reported patients with DOA, DOA+, and Behr syndrome, being often the first and main symptom. Our patient showed early onset optic atrophy, congenital cataracts, neuromus-

cular disorders, mental retardation, and developmental delay reminiscent of Behr syndrome, expanding the mutation spectrum of $\text{OPA1}$. The genetic findings in this unique case also emphasized the importance of CNVs analysis in diagnosis protocol of Behr syndrome.

**Table 1 In-silico damaging effect prediction of missense variants**

| Softwares/Algorithms | Score | Deleterious/Pathogenicity threshold |
|----------------------|-------|-----------------------------------|
| Clin Predic           | 0.99  | > 0.5                             |
| REVEL                | 0.92  | > 0.5                             |
| M-CAP                | 0.39  | > 0.11                            |
| ReVe                 | 0.99  | > 0.66                            |
| VEST3                | 0.97  | > 0.61                            |
| FATHIMM             | -4.00 | ≤ - 0.92                         |
| SIFT                 | 0.00  | ≤ 0.01                            |
| PolyPhen2-HDIV       | 1.00  | > 0.93                            |
| PolyPhen2-HVAR       | 0.99  | > 0.62                            |
| GERP++               | 5.89  | > 3.86                            |
| CADD                 | 6.33  | > 23.95                           |

**Discussion and conclusion**

Heterozygous mutation of the $\text{OPA1}$ gene, which en-
codes a multifunctional protein located within the mito-

chondrial inner membrane leading to optic atrophy under a dominant inheritance pattern, has been well-
defined and identified in hundreds of patients. Ban et al. [13] reported that $\text{OPA1}$ disease alleles associated with DOA displayed selective defects in several activities, including cardiolipin association, GTP hydrolysis, and membrane tabulation. Twenty percent of those patients with only one $\text{OPA1}$ mutation manifested a DOA+ phenotype, presenting extra-ocular manifestations. Yu-

Wai-Man et al. [5] revealed that there was a 2- to 4-fold increase in the mitochondrial DNA copy number at the single-fiber level, and greater mitochondrial DNA prolif-
eration in cytochrome oxidase-negative skeletal muscle fibers induced by $\text{OPA1}$ mutations in patients with DOA+ features.

Compound heterozygous mutations in $\text{OPA1}$ have been reported in a few patients with DOA+, or even more severe and early onset phenotypes. Schaaf et al. reported two siblings presenting severe DOA+ features and identified biallelic $\text{OPA1}$ mutations in these individuals [14]. Each parent was heterozygous for one of the mutations and also manifested mild related phenotypes. This indicated clinical heterogeneity of those mutations and a possible dosage effect of the OPA variants. Alessia et al. [15] reviewed reported cases with biallelic $\text{OPA1}$ variants and found that most patients carried the p.Ile437Met missense vari-
tant that was considered hypomorphic, or with very low potential pathogenicity. The p.Ile437Met missense variant did not result in clinical symptoms of auto-

somal DOA in the heterozygous or homozygous states. Thus, the p.Ile437Met missense variant was thought to contribute consistently to modulating the phenotype in $\text{OPA1}$ compound heterozygous subjects,
C <sup>p</sup>.Leu730Ser, detected in the proband has not been re-ported previously in DOA-related phenotypes. A con-current chromosomal deletion in the proband contributed to the pathogenesis of a phenotype reminiscent of Behr syndrome in a recessive mode with rare missense variants. This rare case will help in further exploring and understanding the detailed pathologic mechanism in OPA1 patients.

Abbreviations
OPA: Optic atrophy; WES: Whole exome sequencing; DOA: Dominant optic atrophy; CNVs: Copy number variants; GTP: Guanosine triphosphate

Acknowledgements
Not applicable.

Authors’ contributions
TZ and SZW wrote the initial draft, and YZ and HHL revised the draft. TZ, LYL, YG, and XXL are pediatricians who were responsible for diagnosing and treating this child. XBX and SC were in charge of collecting the clinical data and following up with the patient. All authors approved the final manuscript.

Funding
The study was funded by the Liuzhou Science and Technology Bureau Project (2017BD20201 and 2017BH20311). The first author is the PI of the Liuzhou Science and Technology Bureau Project (2017BD20201 and 2017BH20311). ZT, the first author, is the PI of Project 2017BH20311; LHH is the PI of Project 2017BD20201, and they co-designed this study. Funding bodies of the Liuzhou Science and Technology Bureau Project (2017BD20201) played the role of analysis and interpretation of data, Funding bodies of the Liuzhou Science and Technology Bureau Project (2017BH20311) played the role of sample and data collection, as well as write this manuscript.

Fig. 2 a Sanger sequencing of the proband and his parents showed that the proband was homozygous, the father heterozygous, and the mother wild-type. b Sketch map of the chromosome 3 copy number state for the proband from the CNVkit. The microdeletion is indicated by a red arrow with the copy number ratio at – 1.0. c Chromosomal microarray analysis precisely mapping the deletion on 3q28q29 and covering the OPA1 gene.
Availiability of data and materials
Data used during the current study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate
Written informed consent was obtained from the parents of the child for providing a blood sample for genetic testing and publication of this case report. The study was approved by the Research Ethics Committee at Liuzhou Maternity and Child Healthcare Hospital.

Consent for publication
Written consent for publication was obtained from the patient’s legal guardian.

Competing interests
The authors declare that they have no competing interests.

Received: 25 February 2020 Accepted: 20 August 2020
Published online: 03 September 2020

References
1. Lee H, Smith SB, Yoon Y. The short variant of the mitochondrial dynamin OPA1 maintains mitochondrial energetics and cristae structure. J Biol Chem. 2017;292(17):7115–30.
2. Oldak M, FEDEROWICZ A, Szulborski K, Wierzbowska J, Kosinska J, PIOSKI R, SZAFLIK JP, SZAFLIK J. Detection of a novel premature stop codon in the OPA1 gene in autosomal dominant optic atrophy. Acta Ophthalmol. 2012;90(2):248–9.
3. May-Yung Yen MAWM. Novel mutations of the OPA1 gene in Chinese dominant optic atrophy. Ophthalmology. 2010;117(2):392–6.
4. Ahmad KE, Davis RL, Sue CM. A novel OPA1 mutation causing variable age of onset autosomal dominant optic atrophy plus in an Australian family. J Neurol. 2015;262(10):2323–8.
5. Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AE, Auer-Grumbach M, Toscano A, Musumeci O, Valentino ML, Caporali L, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010;133(Pt 7):771–86.
6. Yu-Wai-Man P, Ballie M, Atawam A, Chinnery PF, Griffiths PG. Pattern of retinal ganglion cell loss in dominant optic atrophy due to OPA1 mutations. EYE. 2011;25(5):596–602.
7. Yu-Wai-Man P, Chinnery PF. Dominant optic atrophy: novel OPA1 mutations and revised prevalence estimates. Ophthalmology. 2013;120(8):1712.
8. Bonneau D, Colin E, Oca F, Fereil M, Chevrollier A, Guéguen N, Desquert-Dumas V, N’Guyen S, Barth M, Zanlonghi X, et al. Early-onset Behr syndrome due to compound heterozygous mutations in OPA1. BRAIN. 2014;137(10):e301.
9. Marelli C, Arnati-Bonneau P, Reynier P, Layet V, Layet A, Stevanin G, Brissaud E, Bonneau D, Durr A, Brice A. Heterozygous OPA1 mutations in Behr syndrome. BRAIN. 2011;134(4):e169–70.
10. Felcic AC, Godeiro-Junior C, Alberto LG, Pinto APM, Sallum JMF, Teive HG, Barsottini OGP. Familial Behr syndrome-like phenotype with autosomal dominant inheritance. Parkinsonism Relat Disord. 2008;14(4):370–2.
11. Carelli V, Sabatelli M, Carrozzo R, Rizza T, Schimpf S, Wissinger B, Zanella C, Rugolo M, La Morgia C, Caporali L, et al. ‘Behr syndrome’ with OPA1 compound heterozygote mutations. Brain. 2014;137(1):e321.
12. Hu X, Li N, Xu Y, Li G, Yu T, Yao RE, Fu L, Wang J, Yin L, Yin Y, et al. Proband-only medical exome sequencing as a cost-effective first-tier genetic diagnostic test for patients without prior molecular tests and clinical diagnosis in a developing country: the China experience. Genet Med. 2018;20(9):1045–53.
13. Ban T, W. HIA, Song Z, Jinshaw JE, Chan DC. OPA1 disease alleles causing dominant optic atrophy have defects in cardiolipin-stimulated GTP hydrolysis and membrane tubulation. Hum Mol Genet. 2010;19(11):2113–2122.
14. Schaaf CP, Blazo M, Lewis RA, Tonini RE, Takei H, Wang J, Wong L, Scaglia F. Early-onset severe neuromuscular phenotype associated with compound heterozygosity for OPA1 mutations. Mol Genet Metab. 2011;103(4):383–7.
15. Nasca A, Rizza T, D’Ambrosio M, Legati A, Ciolfi A, Diodato D, Calderan C, Carrara G, Lamantea A, Eiello C, et al. Not only dominant, not only optic atrophy: expanding the clinical spectrum associated with OPA1 mutations. ORPHANET J RARE DIS. 2017;12(1):89.
16. Rubegni A, Pisano T, Bachi G, Tessa A, Battini R, Procopio E, Giglio S, Pasqualiello R, Santorelli FM, Guerini R. Leigh-like neuroimaging features associated with new biallelic mutations in OPA1. Eur J Paediatr Neurol. 2017;21(4):671–7.
17. Payne M, Yang Z, Katz BJ, Warner JEA, Weight CJ, Zhao Y, Pearson ED, Treft RL, Hillman T, Kennedy RJ. Dominant optic atrophy, sensorineural hearing loss, ptosis, and ophthalmoplegia: a syndrome caused by a missense mutation in OPA1. Am J Ophthalmol. 2004;138(5):749–55.
18. Kazamel M, Wong L, Milone M. Novel OPA1 mutation featuring spastic paraparesis and intestinal dysmotility. Mol Genet Metab Rep. 2014;1(1):43–5.
19. Fuhrmann N, Alavi MV, Bitoun P, Weerdmie A, Auburger G, Leo-kottler B, Yu-Wai-Man P, Chinnery PF, Wissinger B. Genomic rearrangements in OPA1 are frequent in patients with autosomal dominant optic atrophy. J Med Genet. 2009;46(2):136–44.
20. Olichon A. Loss of OPA1 Perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. J Biol Chem. 2003;278(10):7743–6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions